Guggenheim analyst Vamil Divan initiated coverage of Aerovate Therapeutics with a Buy rating and $36 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AVTE:
Guggenheim analyst Vamil Divan initiated coverage of Aerovate Therapeutics with a Buy rating and $36 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AVTE: